SG Americas Securities’s Cymabay Therapeutics CBAY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-4,780
| Closed | -$113K | – | 3574 |
|
|
2023
Q4 | $113K | Sell |
4,780
-10,669
| -69% | -$190K | ﹤0.01% | 2679 |
|
|
2023
Q3 | $230K | Buy |
+15,449
| New | +$205K | ﹤0.01% | 2232 |
|
|
2022
Q2 | – | Sell |
-10,900
| Closed | -$34K | – | 3663 |
|
|
2022
Q1 | $34K | Sell |
10,900
-7,917
| -42% | -$24.9K | ﹤0.01% | 2865 |
|
|
2021
Q4 | $64K | Sell |
18,817
-27,261
| -59% | -$103K | ﹤0.01% | 3163 |
|
|
2021
Q3 | $168K | Buy |
+46,078
| New | +$182K | ﹤0.01% | 3345 |
|
|
2021
Q2 | – | Sell |
-13,919
| Closed | -$63K | – | 3330 |
|
|
2021
Q1 | $63K | Sell |
13,919
-5,959
| -30% | -$32.1K | ﹤0.01% | 3142 |
|
|
2020
Q4 | $114K | Buy |
+19,878
| New | +$150K | ﹤0.01% | 2973 |
|
|
2020
Q3 | – | Sell |
-37,948
| Closed | -$132K | – | 3617 |
|
|
2020
Q2 | $132K | Buy |
37,948
+11,190
| +42% | +$32.3K | ﹤0.01% | 3184 |
|
|
2020
Q1 | $40K | Buy |
+26,758
| New | +$44.9K | ﹤0.01% | 3212 |
|
|
2019
Q4 | – | Sell |
-16,612
| Closed | -$85K | – | 3484 |
|
|
2019
Q3 | $85K | Buy |
+16,612
| New | +$101K | ﹤0.01% | 2751 |
|
Other funds holding CBAY
SG Americas Securities's CBAY Position: Q1 2024 in Review
SG Americas Securities sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 4,780 shares — an estimated $113K sold.
SG Americas Securities first reported a position in CBAY in Q3 2019 and held it in 10 quarters. The position peaked at $230K in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.
- SG Americas Securities reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
- SG Americas Securities sold 4,780 Cymabay Therapeutics shares in Q1 2024, an estimated $113K.
- SG Americas Securities first reported a position in Cymabay Therapeutics in Q3 2019 and held it in 10 quarters.
- SG Americas Securities's Cymabay Therapeutics position peaked at $230K in Q3 2023.
- 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.
Based on SG Americas Securities's 13F filing for Q1 2024, filed 6 May 2024.